USP and Public Policy
Left
Refine Your Search
USP supports leadership on the release of the discussion draft of the “Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act” (“PREVENT Pandemics Act."
Learn More
USP supported S. 4090, the “Dietary Supplement Listing Act of 2022.”
Learn More
USP appreciates the opportunity to provide comments for the National Conference on Weights and Measures’ (NCWM) consideration on proposed commercial measurement standards for cannabis and cannabis-…
Learn More
USP urged the California Assembly to consider highlighting the need for quality specifications as part of the regulatory framework for California Assembly Bill AB-45 and Senate Bill SB-235, “…
Learn More
USP Statement to the WHO on the quality of hand sanitizers, or handrubs, as related to public health emergencies: preparedness and response.
Learn More
USP greatly appreciate the opportunity to provide feedback on the Cannabis Administration and Opportunity Act (CAOA) Discussion Draft.
Learn More
USP appreciates the opportunity to comment on the State of New York’s proposed rulemaking, “Addition of Part 1005 to Title 10 NYCARR (Cannabinoid Hemp).”
Learn More
USP appreciates the opportunity to comment on the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q13 harmonized guideline draft.
Learn More
USP appreciates the opportunity to comment on the Food and Drug Administration’s (FDA or the Agency) Guidance for Industry, Control of Nitrosamine Impurities in Human Drugs.
Learn More
USP appreciates the opportunity to comment on FDA’s draft guidance Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research.
Learn More